Ophthalmology

It was previously announced that CT103A received FDA clearance of its investigational new drug application for the treatment of relapsed/refractory (r/r) multiple myeloma.

A phase 1 clinical trial of EXG102-031 is expected to initiate in the first quarter of 2023.

The director of clinical research at Sierra Eye Associates discussed data from the phase 1/2 PRISM study.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The company expects to provide initial data from the trial in the second half of this year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review some of our most-viewed coverage of advancements in cell therapies, including study data and clinical trial updates.

Review some of our most-viewed coverage of advancements in gene therapies, including study data and clinical trial updates.

Review some of our most-viewed interviews with clinicians, researchers, and biotech companies about expanding applications of cell and gene therapies.

NFS-02 previously received orphan drug designation from the FDA in January of this year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The agency granted OCU400 orphan drug designation for additional indications and agreed to a phase 3 trial design for NeoCart.

With several newly approved therapies hitting the market and an overflowing pipeline, the FDA has stepped in to help keep the burgeoning world of biotech on track.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Initial safety data from the PRODYGY study are expected in 2023.

Review top news and interview highlights from the week ending December 2, 2022.

OPGx-001 is the first of Opus Genetics’ gene therapy candidates for treating LCA to enter clinical trials.

The director of clinical research at Sierra Eye Associates discussed unmet needs in patients with wet AMD.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending November 18, 2022.

Editas has paused enrollment in the BRILLIANCE trial after efficacy was only seen in a very small subset of patients.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

4D Molecular Therapeutics plans to initiate enrollment in the phase 2 randomized portion of the study in the first quarter of 2023.

The Genomics and Epigenetic Guided Safe Harbor mapper will aid in the future design of gene-editing therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Among the trial’s high dose cohort, 80% of patients did not require supplemental injections for over 2 years.

Review top news and interview highlights from the week ending November 4, 2022.

Updated data from the ALTITUDE trial were presented at the 55th ARS meeting in Pasadena, CA.